We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Blood Test for Presence of Autoimmune Antibodies Could Help Identify COVID-19 Patients at Risk of Developing Severe Disease

By LabMedica International staff writers
Posted on 10 Sep 2021
A new study has detected special immune system defense molecules, called autoimmune antibodies, in the blood of more than a third of men and women on admission to hospital and confirmed to have COVID-19.

Among the findings of the study by researchers at NYU Grossman School of Medicine (New York, NY, USA) is that a subset of these autoimmune antibodies that bind to DNA or to a particular type of fat molecule, a lipid called phosphatidylserine, were more often twice as abundant at the start of coronavirus infection in those whose conditions worsened quickly than in those whose health did not decline. More...
Patients with these elevated levels of autoimmune antibodies were five to seven times more likely to develop severe disease than those whose antibodies levels were stable.

People hospitalized with life-threatening cases of COVID-19, researchers say, required intensive care and a mechanical ventilator to help them breathe while those who had lower levels of these autoantibodies usually breathed on their own and largely recovered. The latest work is based on the nature of antibodies, immune proteins that target invading bacteria and viruses. By contrast, autoimmune antibodies attack an infected person’s own cells and molecules. This includes lipids and genetic material, or DNA, which are known to spill into the bloodstream as cells are killed by disease, such as COVID-19.

For the new study, researchers examined the medical records and blood tests from 115 White, Black, Asian, and Hispanic men and women hospitalized for COVID-19 at NYU Langone hospitals between April and June 2020. Roughly equal numbers had severe disease from which they either survived or died, or did not require intensive care and recovered quickly. Test results for more than 100 measurements, such as blood oxygen levels, liver enzymes, and kidney function, were compared with levels of autoimmune antibodies. The researchers designed the analysis to learn whether common autoimmune antibodies were present in COVID-19, as other studies in other infectious diseases had already suggested, and whether or not variations in blood levels were tied to how sick people became.

The researchers found that 36% of the study participants had autoimmune antibodies when they were admitted to the hospital. Levels of anti-DNA and anti-phosphatidylserine antibodies were then strongly linked to severity of illness. Specifically, 86% and 93% of patients with high levels of anti-DNA and anti-phosphatidylserine antibodies, respectively, experienced severe COVID-19. Levels of anti-DNA antibodies were also linked to increases in blood coagulation (thrombosis) and cell death (lysis), especially in muscle tissue. Researchers say both thrombosis, which can lead to life-threatening blood clots, and damage to muscle tissue, especially in the heart, have been observed in the most serious cases of COVID-19.

Further experiments will be needed to determine if autoimmune antibodies are indeed the “cause or effect” of the blood clotting and cell lysis observed in her team’s study. If found to be causal of cell damage, new COVID-19 treatments could include antibody injections from healthy donors to dilute the presence of autoimmune antibodies. Other experimental therapies under consideration involve biodegradable antigens that attach to autoimmune antibodies and neutralize them, but do not lead to a lasting antibody immune reaction of their own.

“Our study results show that initial blood levels of anti-DNA or anti-phosphatidylserine antibodies were directly linked to the severity of illness in those with COVID-19,” said study co-lead investigator Claudia Gomes, PhD, a postdoctoral fellow at NYU Langone Health.

“While further testing is needed, our findings suggest that a test for the presence of anti-DNA and anti-phosphatidylserine antibodies could help identify those COVID-19 patients admitted to hospital who are most at risk of needing intensive care and who need to be monitored more closely,” added Marisol Zuniga, MS, also a study co-lead investigator at NYU Langone.


Related Links:
NYU Grossman School of Medicine


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.